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A B S T R A C T
The European Code Against Cancer is a set of recommendations to give advice on cancer prevention. Its
4th edition is an update of the 3rd edition, from 2003. Working Groups of independent experts from
different ﬁelds of cancer prevention were appointed to review the recommendations, supported by a
Literature Group to provide scientiﬁc and technical support in the assessment of the scientiﬁc evidence,
through systematic reviews of the literature. Common procedures were developed to guide the experts in
identifying, retrieving, assessing, interpreting and summarizing the scientiﬁc evidence in order to revise
the recommendations. The Code strictly followed the concept of providing advice to European Union
citizens based on the current best available science. The advice, if followed, would be expected to reduce
cancer risk, referring both to avoiding or reducing exposure to carcinogenic agents or changing behaviour
related to cancer risk and to participating in medical interventions able to avert speciﬁc cancers or their
consequences. The information sources and procedures for the review of the scientiﬁc evidence are
described here in detail. The 12 recommendations of the 4th edition of the European Code Against Cancer
were ultimately approved by a Scientiﬁc Committee of leading European cancer and public health
experts.
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The European Code Against Cancer is a set of recommendations
providing advice on the prevention of cancer [1]. The 12 recom-
mendations are addressed to European Union citizens to inform
them about measures they can take to reduce their risk of
developing cancer or dying from cancer (Box 1). Most of the
recommendations deal with avoiding or reducing exposures to
carcinogenic agents or adopting healthy behaviours. Medical
interventions that prevent developing cancer or dying from cancer
in large population groups are also recommended, i.e. participation
in vaccination programmes or organized screening programmes
for early detection. The 4th edition of the European Code Against
Cancer is an update of the 3rd edition, published in 2003 [2]. As
described elsewhere [1], the principles of the 4th edition were that
the recommendations should be suitable for a broad target
audience, refer to actions that individuals can take themselves
to reduce their cancer risk, be clearly and succinctly communicable
to the general population and, importantly, be based on sufﬁcient
scientiﬁc evidence that following the recommendation wouldd https://creativecommons.org/licenses/by-nc-nd/3.0/igo/
Box 1. European Code Against Cancer, 4th Edition.
EUROPEAN CODE AGAINST CANCER
12 ways to reduce your cancer risk
1. Do not smoke. Do not use any form of tobacco.
2. Make your home smoke free. Support smoke-free policies
in your workplace.
3. Take action to be a healthy body weight.
4. Be physically active in everyday life. Limit the time you
spend sitting.
5. Have a healthy diet:
 Eat plenty of whole grains, pulses, vegetables and fruits.
 Limit high-calorie foods (foods high in sugar or fat) and
avoid sugary drinks.
 Avoid processed meat; limit red meat and foods high in
salt.
6.If you drink alcohol of any type, limit your intake. Not
drinking alcohol is better for cancer prevention.
7.Avoid too much sun, especially for children. Use sun
protection. Do not use sunbeds.
8.In the workplace, protect yourself against cancer-causing
substances by following health and safety instructions.
9.Find out if you are exposed to radiation from naturally high
radon levels in your home. Take action to reduce high
radon levels.
10. For women:
 Breastfeeding reduces the mother’s cancer risk. If you
can, breastfeed your baby.
 Hormone replacement therapy (HRT) increases the risk
of certain cancers. Limit use of HRT.
11.Ensure your children take part in vaccination pro-
grammes for:
 Hepatitis B (for newborns).
 Human papillomavirus (HPV) (for girls).
12. Take part in organized cancer screening programmes for:
 Bowel cancer (men and women).
 Breast cancer (women).
 Cervical cancer (women).
The European Code Against Cancer focuses on actions that
individual citizens can take to help prevent cancer. Success-
ful cancer prevention requires these individual actions to be
supported by governmental policies and actions.
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the recommendations, common procedures were developed to
guide the scientiﬁc experts in retrieving, assessing, interpreting
and summarizing the evidence. Supplementary information in
question-and-answer format, explaining and providing additional
information on the 12 recommendations as well as cancer
prevention topics not covered in the Code, was developed
following the same methodology [1,3].
In the present paper, those procedures are described in detail.
2. General considerations on the methods
2.1. Causality and effectiveness in recommendations for cancer
prevention
Recommendations in the Code and corresponding question and
answers can be divided into two broader categories, with
implications for the required nature and level of evidence. The
ﬁrst type of recommendation focuses on established causes of
cancer and risks of developing cancer that people can avoid or
reduce. The second type of recommendation deals with medical
interventions able to avert speciﬁc cancers or their consequences.Related to the ﬁrst type of recommendation, the supporting
evidence results from the assessment of the causality of associations
between exposure and disease. A recommendation to avoid or
reduce a given exposure or risk is justiﬁed if the available scientiﬁc
evidence is sufﬁcient to infer a causal association. The Code strictly
follows this concept and aims to provide advice to European Union
(EU) citizens as recommendations that, if followed, would be
expected to reduce cancer risk. This refers both to avoiding or
reducing exposure to carcinogenic agents (such as tobacco or
ultraviolet radiation [UVR]) and to changing behaviour related to
cancer risk (such as sedentary behaviour).
Related to the second type of recommendation, the Code aims
to provide information on medical interventions that, if followed,
reduce the risk of developing or dying from speciﬁc cancers.
Medical interventions include vaccinations, for instance to prevent
viral infection that can ultimately lead to development of cancer
[4,5]. Some interventions aim to prevent cancer by early detection
or treatment of precancerous lesions, for instance of the cervix [6]
or colon and rectum [7]. They may also indicate how to mitigate
progression of cancer, such as through detection and treatment of
early invasive breast cancer [8].
The supporting evidence for interventions requires evaluation
of the efﬁcacy and effectiveness of such deﬁned actions. Like any
health intervention, preventive interventions may also have
harmful effects. Therefore, careful consideration is given to the
balance between the potential beneﬁt and the potential harm
before an intervention can be recommended. This applies
particularly to recommendations for the general public or large
groups of the general population, due to the very large numbers of
people exposed to the intervention in order to prevent relatively
few cases of disease.
2.2. Process for reviewing the relevant evidence
For the update of the European Code Against Cancer, Working
Groups (WGs) of independent scientiﬁc experts in different ﬁelds
of cancer research and prevention were appointed by the European
Code Against Cancer scientiﬁc secretariat at the International
Agency for Research on Cancer (IARC). The six topic-related WGs
dealt with: smoking and other forms of tobacco use (Tobacco WG);
diet, physical activity, body weight and alcohol (Nutrition WG);
environmental, occupational, and pharmaceutical exposures
(Environment WG); radiation (Radiation WG); infections and
vaccinations (Infections and Vaccinations WG); and cancer
screening (Screening WG). The WGs were asked to review the
recommendations in the 3rd edition of the Code and to update
them if necessary. The recommendations proposed by the WGs
were based on a consensus among the experts on the interpreta-
tion of the evidence and an appropriate balance between the
beneﬁt and risk of following the recommendations. The ﬁnal form
of the recommendations was ultimately approved by a Scientiﬁc
Committee of leading experts from major European cancer
research or public health institutions [1], following an iterative
discussion with the WGs.
A common methodology was developed on how to assess the
scientiﬁc evidence forming the basis of any recommendation (to
avoid or reduce exposure, to change behaviour, or to participate in
interventions) and the corresponding questions and answers of
additional public health messages [1].
A Literature Group of epidemiologists experienced in system-
atic review of the scientiﬁc literature was established to provide
scientiﬁc and technical support to the WGs in the identiﬁcation
and analysis of the relevant scientiﬁc evidence. In this case, the
assessment of the evidence was based on the systematic review of
the literature according to the following steps: deﬁning clinical
questions, searching the relevant literature, assessing the
Table 1
Correspondence between IARC Monographs and WCRF/AICR reports in overall levels of evidence and whether the evidence was sufﬁcient to consider a recommendation for
the European Code against Cancer
IARC monographs WCRF/AICR reports
Sufﬁcient evidence for Code recommendations
Group 1—carcinogenic to humans Convincing evidence for causal relationship
Sufﬁcient evidence of carcinogenicity in humans. Overall evidence strong enough to justify goals and recommendations to reduce
cancer incidence.
Generally required: Causal relationship highly unlikely to be modiﬁed by new evidence in foreseeable
future. Generally required:
 Several criteria of causality fulﬁlled [52]
 Strong association (large relative risk)
 Replication of results in several studies of same design or with different
epidemiological approaches or different exposure conditions
 Explanation for inconsistent results, if present
 Graded response to exposure (not mandatory)
 Decline in risk after stopping exposure
Additional factors may increase conﬁdence in causal relationship:
 Induction of multiple tumour types, temporality
 Precision of effect estimates
 Plausibility, coherence of overall database
 Biomarker data
Exceptionally with less than sufﬁcient evidence of carcinogenicity in humans but
with sufﬁcient evidence of carcinogenicity in experimental animals and strong
evidence in exposed humans of a relevant mechanism of carcinogenicity
 Evidence from more than one study type and at least two independent cohort
studies
 No substantial unexplained heterogeneity within or between study types or in
different populations regarding presence or absence of association, or direction of
effect
 Good quality studies to conﬁdently exclude the possibility that the observed
association results from random or systematic error, including confounding,
measurement error, and selection bias
 Presence of a plausible biological gradient (“dose–response”) in the association
(gradient need not be linear or in same direction across different levels of
exposure, so long as this can be explained plausibly)
 Strong and plausible experimental evidence, either from human studies or
relevant animal models, that typical human exposures can lead to relevant cancer
outcomes
Probable evidence for causal relationship
Overall evidence strong enough to justify goals and recommendations to reduce
cancer incidence, but not as strong as convincing category. Generally required:
 Evidence from at least two independent cohort studies, or at least ﬁve case–
control studies
 No substantial unexplained heterogeneity between or within study types in the
presence or absence of an association, or direction of effect
 Good quality studies to conﬁdently exclude the possibility that the observed
association results from random or systematic error, including confounding,
measurement error, and selection bias
 Evidence for biological plausibility
Not sufﬁcient evidence for Code recommendations
Group 2A—probably carcinogenic to humans
Limited evidence of carcinogenicity in humans and sufﬁcient evidence of
carcinogenicity in experimental animals.
 In some cases: inadequate evidence of carcinogenicity in humans and sufﬁcient
evidence of carcinogenicity in experimental animals and strong evidence that
carcinogenesis is mediated by a mechanism that also operates in humans
 Exceptionally: limited evidence of carcinogenicity in humans provides the sole
basis for classiﬁcation
 In some cases mechanistic considerations show that agent belongs to a class of
agents for which one or more members have been classiﬁed in Group 1 or Group
2A
Group 2B—possibly carcinogenic to humans Limited—suggestive evidence for causal relationship
Limited evidence of carcinogenicity in humans and less than sufﬁcient evidence of
carcinogenicity in experimental animals.
Overall evidence too limited for probable or convincing causal judgement, but
suggesting direction of effect.
 In some cases: inadequate evidence of carcinogenicity in humans and sufﬁcient
evidence of carcinogenicity in experimental animals
 In some instances: inadequate evidence of carcinogenicity in humans and less
than sufﬁcient evidence of carcinogenicity in experimental animals and
supporting evidence from mechanistic and other relevant data
 In some cases there may only be strong evidence from mechanistic and other
relevant data
 Evidence methodologically ﬂawed or limited in amount, but generally showing a
consistent direction of effect
 Recommendations to reduce cancer incidence rarely justiﬁed
Generally required:
 Evidence from at least two independent cohort studies or at least ﬁve case–
control studies
 Direction of effect is generally consistent, although some unexplained
heterogeneity may be present
 Evidence for biological plausibility
Group 3—not classiﬁable as to its carcinogenicity to humans Limited—no conclusion
Inadequate evidence of carcinogenicity in humans and inadequate or limited
evidence of carcinogenicity in experimental animals.
Evidence is so limited that no ﬁrm conclusion can be made.
 Exceptionally: inadequate evidence of carcinogenicity in humans and sufﬁcient
evidence of carcinogenicity in experimental studies and strong evidence that the
mechanism of carcinogenicity in experimental animals does not operate in
humans
 Agents that do not fall into any other group are also placed in this category
This category represents an entry level, and is intended to allow any exposure for
which there are sufﬁcient data to warrant Panel consideration, but where
insufﬁcient evidence exists to permit a more deﬁnitive grading. This does not
necessarily mean a limited quantity of evidence. A body of evidence for a particular
exposure might be graded “limited – no conclusion” for a number of reasons. The
evidence might be limited by the amount of evidence in terms of the number of
studies available, by inconsistency of direction of effect, by poor quality of studies
(for example, lack of adjustment for known confounders), or by any combination of
these factors
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Table 1 (Continued)
IARC monographs WCRF/AICR reports
Group 4—probably not carcinogenic to humans
Evidence suggesting lack of carcinogenicity in humans and in experimental animals
 Evidence suggesting lack of carcinogenicity: There are several adequate studies
covering the full range of levels of exposure that humans are known to encounter,
which are mutually consistent in not showing a positive association between
exposure to the agent and any studied cancer at any observed level of exposure.
The results from these studies alone or combined should have narrow conﬁdence
intervals with an upper limit close to the null value (e.g. a relative risk of 1.0). Bias
and confounding should be ruled out with reasonable conﬁdence, and the studies
should have an adequate length of follow-up. A conclusion of evidence suggesting
lack of carcinogenicity is inevitably limited to the cancer sites, conditions and
levels of exposure, and length of observation covered by the available studies. In
addition, the possibility of a very small risk at the levels of exposure studied can
never be excluded.
 Evidence suggesting lack of carcinogenicity: Adequate studies involving at least
two species are available which show that, within the limits of the tests used, the
agent is not carcinogenic. A conclusion of evidence suggesting lack of
carcinogenicity is inevitably limited to the species, tumour sites, age at exposure,
and conditions and levels of exposure studied.
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evidence tables and summary documents with the most relevant
information and the level of evidence about the question posed by
the WG members.
As described in more detail below, it was not the task of WG
members to review the totality of scientiﬁc evidence, but ensuring
the recommendations were based on sufﬁcient scientiﬁc evidence
for preventing cancer or its consequences, if following them. When
sufﬁcient scientiﬁc evidence was available from authoritative
sources considered as scientiﬁcally reliable, they were used as the
evidence base for the recommendations. Prerequisite was that
these sources were following a rigorous procedure of assessing the
scientiﬁc evidence, complete and recent.
For conﬁrming evidence on the carcinogenicity to humans, the
following sources were deﬁned as fulﬁlling these criteria:
- the IARC Monographs on the Evaluation of Carcinogenic Risks to
Humans (see Section 3.1);
- the Expert Report and Continuous Update Project (CUP) of the
World Cancer Research Fund and the American Institute of
Cancer Research (WCRF/AICR) (see Section 3.1).
The methods of IARC and WCRF/AICR are similar in their main
principles (Table 1): both consider as a primary source of evidence
data from human studies, followed by evidence from studies in
experimental animals, and mechanistic data. However, the second
category in the classiﬁcation of carcinogenicity differs between the
two methods. While WCRF/AICR’s deﬁnition for “Probable
evidence for causal relationship” refers to “overall evidence strong
enough to justify goals and recommendations to reduce cancer
incidence, but not as strong as convincing category”; the IARC
Monographs’ classiﬁcation of “Group 2A—probably carcinogenic to
humans” indicates “limited evidence of carcinogenicity in
humans” (see Table 1).
In the case of the medical interventions, the following
authoritative sources were examined:
- the IARC Handbooks of Cancer Prevention (see Section 3.1);
- the World Health Organization (WHO) position papers (see
Section 3.1);
- the European Guidelines for Quality Assurance in Cancer
Screening (see Section 3.1).
When the systematic reviews provided by those sources were
not sufﬁciently recent, a systematic search of the most recentliterature was performed to see whether it would alter the earlier
assessment. This applied in particular to some of the questions and
answers related to the recommendations.
Below (Section 4), a detailed description is provided of how
these procedures for evaluating the evidence were used for each of
the 12 individual recommendations.
3. Criteria for updating the evidence
The following criteria for updating the evidence for the
recommendations and their corresponding questions and answers
were adopted (Fig. 1).
As explained elsewhere [1], there had to be sufﬁcient scientiﬁc
evidence that following the recommendation to avoid or reduce
exposure to a harmful agent, or to adopt a healthy behaviour,
would reduce a person’s risk of developing cancer. The WG made
this decision based on:
- whether the exposure was classiﬁed as a Group 1 carcinogen
(“carcinogenic to humans”) in the IARC Monographs, and
whether the more recent scientiﬁc literature appearing after
the Monograph did not alter this assessment [9,10]
- whether the exposure or behaviour was classiﬁed as showing
strong evidence (convincing or probable causal relationship with
the cancer risk) by the Expert Report and Continuous Update
Project (CUP) of WCRF/AICR, and whether the more recent
scientiﬁc literature appearing after the WCRF/AICR reports did
not alter this assessment [11,12]
- whether the WG’s own reviews of the most recent scientiﬁc
literature provided evidence corresponding to a classiﬁcation of
a Group 1 carcinogen by the IARC Monographs or strong evidence
by WCRF/AICR.
For the recommendations and questions and answers based on
interventions for cancer prevention (e.g. on tobacco cessation,
vaccination or screening), evidence on the effectiveness of
interventions was retrieved initially from the IARC Handbooks
of Cancer Prevention [6,8,13], the WHO position papers [4,5,14] and
the European Guidelines for Quality Assurance in Cancer Screening
[15–18].
The WG made a recommendation based on whether the
systematic literature review conducted by the WG and the
Literature Group provided evidence on interventions that the
WG members judged to be sufﬁciently strong.
Fig. 1. Criteria used for grading the evidence of causality and of effectiveness for each recommendation of the 4th edition of the European Code Against Cancer (similarly
applied to the questions and answers).
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Comprehensive reviews of the relevant literature have been
conducted by IARC in its programme of Monographs on the
Evaluation of Carcinogenic Risks to Humans. The programme has
been running since 1971, and to date 971 agents have been
evaluated and classiﬁed as to their carcinogenicity to humans
[9,10]. The topics covered by the IARC Monographs are regularly
reviewed in international advisory meetings [19]. New Mono-
graphs evaluations are also conducted on previously reviewed
topics if new evidence indicates the need for an update or a re-
assessment. Depending on the evidence, the grading may range
from strong evidence of carcinogenicity to evidence suggesting
lack of carcinogenicity (Table 1). A similar, comprehensive
approach to the assessment of causality and cancer risk has been
taken by WCRF/AICR in their Second Expert Report “Food,
Nutrition, Physical Activity, and the Prevention of Cancer: a Global
Perspective” and the Continuous Update Project [11,12]. For the
Report [11], 20 systematic literature reviews, covering 19 cancer
sites as well as weight gain and the development of obesity, were
commissioned from independent academic research teams [20]. In
an extensive consultative process involving the centres participat-
ing in the literature reviews, experts from the United Nations and
other international organizations, the multidisciplinary panel of
experts considered the body of evidence as a whole, in order to
reach an overall evaluation of whether a given factor plays a causal
role in the development of or protection from cancer in humans.
As stated above, the two methods differ as regards the second
category in the classiﬁcation of carcinogenicity (Table 1).
The IARC Handbooks of Cancer Prevention were launched in
1995 to complement the IARC Monographs’ evaluations of
carcinogenic hazards with evaluations of the scientiﬁc evidence
on the cancer-preventive potential of chemopreventive agents and
of primary and secondary prevention interventions. The working
procedures and the evaluation scheme of the IARC Handbooks of
Cancer Prevention closely mirror those of the IARC Monographs.
Interdisciplinary working groups of expert scientists review the
published studies and evaluate the weight of the evidence that an
agent or activity can prevent cancer [21].
The WHO position papers on hepatitis B virus (HBV) and human
papillomavirus (HPV) vaccines belong to a series of regularly
updated position papers on vaccines and vaccine combinations
against diseases that have an international public health impact.
These papers are concerned primarily with the use of vaccines in
large-scale immunization programmes. The papers are reviewed
by external experts and WHO staff, and reviewed and endorsed by
the WHO Strategic Advisory Group of Experts (SAGE) on
Immunization. The Grades of Recommendation, Assessment,
Development and Evaluation (GRADE) methodology is used to
systematically assess the quality of available evidence [22].
The European Guidelines for Quality Assurance in Cancer
Screening have been developed by experts and published by the
European Commission. They cover all aspects of colorectal, breast
and cervical cancer screening and provide guiding principles and
detailed protocols, standards and recommendations that, if
followed, ensure that screening services of high quality are
provided to the population. Recommendations for breast and
cervical cancer screening quality assurance are based on expert
consensus [15–17], while recommendations for colorectal cancer
screening quality assurance are based on the systematic review of
the literature [18].
3.2. Steps undertaken in systematic reviews
The clinical questions initially agreed upon and formulated by
the experts of each WG (Supplementary data 1) were developedaccording to the PICOS method [23–25]:
P: patients/population characteristics.
I: intervention on which the question is focused.
C: comparison intervention/control/reference group.
O: outcome measure relevant for the clinical question
S: study design on which to base the evidence search.
The PICOS components of each prioritized question were used
by the Literature Group to deﬁne speciﬁc keywords used in
comprehensive bibliographic searches.
Bibliographic searches were performed on the Cochrane
Library, Medline, Embase, and PsycINFO for articles appearing
between 1/1/2000 and 31/1/2013 using MeSH terms and free text
words. Articles suggested by the WG members, if published within
the same time period, were added to the literature base. If a large
amount of literature for a given topic was retrieved, preference was
given in the ﬁrst instance to systematic reviewed published
recently (since 2007). If updated systematic reviews were
retrieved addressing the PICOS questions, the search for primary
studies was limited to those studies published after the last search
date of the most recently published systematic review (e.g. when a
systematic review that searched primary studies until February
2006 was retrieved, the Literature Group only searched primary
studies published since 2006). Studies fulﬁlling the inclusion
criteria both for study design and for clinical questions published
after the deadline 31/1/2013 were considered and included if
proposed by the WG members and if they would change the body
of evidence. In the case of retrieval of many systematic reviews
addressing the same PICOS question, only the “best” systematic
reviews were considered. The criteria for selection of the best
reviews were: (i) the results of the methodological quality
assessment, (ii) the update of the bibliographic search and (iii)
the veriﬁcation that the reviews included the same primary studies
(overlapping). The included reviews were therefore those that
were most up-to-date, of the highest methodological quality, and
included the largest number of primary studies.
The inclusion criteria for primary studies were as follows. For
each kind of question (effectiveness, diagnostic accuracy, accept-
ability and compliance) a hierarchy of the study designs to be
considered and inclusion/exclusion criteria was produced by the
Literature Group. For studies on effectiveness, randomized
controlled trials (RCTs) were considered as the best source of
evidence. For studies on diagnostic accuracy, cross-sectional
studies with veriﬁcation by reference standard were considered
as the best source of evidence.
The quality assessment of evidence (systematic reviews and
primary studies) on the effectiveness of interventions was
performed using criteria extracted from published and validated
checklists (Supplementary data 2).
For each question or group of questions pertaining to the same
topic, the Literature Group provided:
- for each included study: an evidence table with the main
characteristics of the study (study design, objective of the study,
comparisons, participant characteristics, outcome measures,
results, methodological quality, level of evidence) (Supplemen-
tary data 3)
- a summary document providing a description of the search
strategy used for each database, a synthesis of the number, types
and characteristics of included studies, the overlapping of
primary studies when selecting systematic reviews, the overall
methodological quality and the main methodological ﬂaws,
their results, the conclusions and the overall level of evidence.
(Supplementary data 4).
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I multiple RCTs of reasonable sample size, or their systematic
reviews;
II one RCT of reasonable sample size, or 3 or fewer RCTs with small
sample size;
III prospective cohort studies or nested case–control studies, or
their systematic reviews; diagnostic cross-sectional accuracy
studies or their systematic reviews;
IV retrospective case–control studies or their systematic reviews,
time series analysis;
V case series; before–after studies without control group, cross-
sectional surveys;
VI expert opinion.
4. Sources of evidence
For each of the 12 recommendations and their corresponding
questions and answers, the applied methodology and the sources
of evidence were the following.
“1. Do not smoke. Do not use any form of tobacco.”
Evidence on the causal association between smoking and
cancer was assessed as convincing for the haematopoietic system
(speciﬁcally, myeloid leukaemia), for cancers of the cervix,
colorectum, kidney, larynx, liver, lung, nasal cavity and paranasal
sinus, oesophagus, oral cavity, ovary, pancreas, pharynx (naso-,
oro-, and hypo-pharynx), stomach, ureter, and urinary bladder, and
for hepatoblastoma (in the children of smokers), as extensively
documented in the IARC Monographs [10,26,27]. Evidence on the
causal association between smokeless tobacco overall and cancer
was assessed as convincing for cancers of the oesophagus, oral
cavity, and pancreas, from the IARC Monographs [10,27,28] and
relevant studies suggested by the WG members [29].
Evidence on the reduction in risk of cancer and of cancer death
after smoking cessation was based on the work reported in the
IARC Handbooks of Cancer Prevention Volume 11 [13] and on
evidence from milestone studies with recently reported follow-up
[29], while the effectiveness of interventions to stop smoking was
assessed using 10 clinical PICOS-based questions (Supplementary
data 1) for systematic literature searches [3,29].
“2. Make your home smoke free. Support smoke-free policies in
your workplace.”
Evidence on the causal association between second-hand
tobacco smoke and cancer was assessed as convincing for lung
cancer, from the IARC Monographs [10,26,27].
Evidence on the effectiveness of smoke-free policies in reducing
exposure to second-hand tobacco smoke in different environ-
ments, including voluntary smoking restrictions in the residential
home, was assessed from the IARC Handbooks of Cancer
Prevention Volume 13 [30] and relevant consistent studies
suggested by the WG members [29].
“3. Take action to be a healthy body weight.”
Evidence on the causal association between excess body weight
and cancer was assessed and updated as convincing for cancers of
the breast (postmenopausal), colorectum, endometrium, gall
bladder, kidney, oesophagus, ovary, pancreas and prostate
(advanced), from WCRF/AICR Continuous Update Project (CUP)
[11,12,31], the IARC Handbooks of Cancer Prevention [32] and
relevant studies suggested by the WG members [33].
“4. Be physically active in everyday life. Limit the time you
spend sitting.”Evidence on the protective association between physical
activity and cancer was assessed and updated as convincing for
colorectal cancers and endometrial cancers, from WCRF/AICR CUP
[11,12], the IARC Handbooks of Cancer Prevention [32] and relevant
studies suggested by the WG members [34].
Evidence that a sedentary lifestyle causes weight gain,
overweight, and obesity was assessed as convincing by the
WCRF/AICR Panel [11].
“5. Have a healthy diet:
 Eat plenty of whole grains, pulses, vegetables and fruits.
 Limit high-calorie foods (foods high in sugar or fat) and avoid
sugary drinks.
 Avoid processed meat; limit red meat and foods high in salt.”
Evidence on the protective association between dietary ﬁbre
and colorectal cancer was assessed and updated as convincing,
from the WCRF/AICR CUP [12] and relevant studies suggested by
the WG members [35].
Evidence that diets rich in high-calorie foods, such as fatty and
sugary foods, and in sugary beverages lead to excess calorie intake
and promote obesity, and in turn lead to an increased risk of cancer,
was assessed as convincing by the WCRF/AICR [35].
Evidence on the causal association between high intakes of red
meat and processed meat and colorectal cancer was assessed and
updated as convincing by the WCRF/AICR CUP [12].
Evidence on the association between salt intake and stomach
cancer was assessed from the WCRF/AICR [11] and relevant recent
studies suggested by the WG members [35], to conclude the
evidence to be strong enough to justify the recommendation.
“6. If you drink alcohol of any type, limit your intake. Not
drinking alcohol is better for cancer prevention.”
Evidence on the causal association between alcohol and cancer
was assessed as convincing for cancers of the colon, female breast,
larynx, liver, oesophagus, oral cavity, pharynx, and rectum, from
the IARC Monographs [36], the WCRF/AICR CUP [37,38] and
relevant studies suggested by the WG members [39].
“7. Avoid too much sun, especially for children. Use sun
protection. Do not use sunbeds.”
Evidence on the causal association between exposure to UVR
and cancer was assessed as convincing for all types of skin cancer,
from the IARC Monographs [40] and relevant studies suggested by
the WG members [41]. Evidence on the causal association between
UVR-emitting devices (e.g. sunbeds) and skin cancer was assessed
as convincing by the IARC Monographs for UVR [40] and was
conﬁrmed by a recent systematic review and meta-analysis [41].
Evidence on limiting exposure to UVR or sunlight and possible
resulting vitamin D deﬁciency was assessed by systematic
literature review based on 1 clinical PICOS-based question
(Supplementary data 1) [3].
“8. In the workplace, protect yourself against cancer-causing
substances by following health and safety instructions.”
Evidence on the causal association between 44 chemical
exposures in the workplace and cancer (including cancers of the
larynx, liver, lung, nasopharynx, ovary, stomach, and urinary
bladder, as well as non-melanoma skin cancer, leukaemia and
lymphoma, mesothelioma, and sinonasal cancer) was assessed as
convincing, from the IARC Monographs [10] and relevant studies
suggested by the WG members [42].
“9. Find out if you are exposed to radiation from naturally high
radon levels in your home. Take action to reduce high radon levels.”
S18 S. Minozzi et al. / Cancer Epidemiology 39S (2015) S11–S19Evidence on the causal association between radon and lung
cancer was assessed as convincing, from the IARC Monographs
[40].
International guidance on radon concentration levels and
practical methods for reducing high radon levels have been
assessed by WHO [43], the International Commission on Radio-
logical Protection (ICRP) [44] and relevant studies suggested by the
WG members [45].
“10. For women:
 Breastfeeding reduces the mother’s cancer risk. If you can,
breastfeed your baby.
 Hormone replacement therapy (HRT) increases the risk of
certain cancers. Limit use of HRT.”
Evidence on the protective association between breastfeeding
and breast cancer was assessed and updated as convincing, from
the WCRF/AICR CUP [12,46] and relevant studies suggested by the
WG members [47]. Evidence on duration of breastfeeding, the
protective effect of breastfeeding on breast cancer risk, and the
effect of breastfeeding on women’s weight was assessed from
systematic literature searches based on 2 clinical PICOS-based
questions (Supplementary data 1) [3,47].
Evidence on the causal association between HRT and cancer was
assessed as convincing for cancers of the breast, endometrium, and
ovary, based on the IARC Monographs [10,48] and relevant studies
suggested by the WG members on the basis of an updated
literature review [49].
“11. Ensure your children take part in vaccination programmes
for:
 Hepatitis B (for newborns)
 Human papillomavirus (HPV) (for girls).”
Evidence on the causal association between cancer and
exposure to HBV and HPV has been assessed by the IARC
Monographs Programme [9].
The effectiveness and safety of HBV vaccine assessed in the
latest WHO position paper [14] was updated with systematic
literature searches based on 1 clinical PICOS-based question
(Supplementary data 1) to identify systematic reviews and
individual studies [3,50].
The efﬁcacy and safety of HPV vaccines assessed in the WHO
position papers [4,5] were updated with systematic literature
searches based on 3 clinical PICOS-based questions (Supplemen-
tary data 1) to identify systematic reviews on the efﬁcacy and
safety of HPV vaccines in women, and to identify RCTs on the
efﬁcacy and safety of HPV vaccines in men [3,50].
Evidence on the causal association between cancer and
exposure to hepatitis C virus (HCV), human immunodeﬁciency
virus (HIV) and Helicobacter pylori (H. pylori) has been assessed by
the IARC Monographs Programme [9]. HCV, H. pylori and HIV were
not part of any of the recommendations of the Code but are part of
the infection-related questions and answers. Evidence was
retrieved on the effectiveness of persistent HBV infection
treatment, of persistent HCV infection treatment, and of antire-
troviral treatment in HIV with systematic literature searches based
on 3 clinical PICOS-based questions (Supplementary data 1) [3,50].
“12. Take part in organized cancer screening programmes for:
 Bowel cancer (men and women)
 Breast cancer (women)
 Cervical cancer (women).”For colorectal, cervical, breast, and prostate cancer screening,
the evidence was retrieved initially from the IARC Handbooks of
Cancer Prevention [6,8] and the European Guidelines for Quality
Assurance in Cancer Screening published between 2003 and
January 2013 [15–18]. A systematic update of the evidence on
impact on mortality/incidence, age, interval and optimal test,
further beneﬁts and harms was performed to support the
recommendations using systematic literature searches based on
38 clinical PICOS-based questions (Supplementary data 1) [3,51].
5. Conclusions
The described methodology was consistently followed by the
WGs to review and update the evidence supporting the recom-
mendations in the 4th edition of the European Code Against Cancer
and their related questions and answers. The recommendations
were proposed by the WGs and ultimately approved by the
Scientiﬁc Committee [1].
The objective of the methodology for reviewing and updating
the European Code Against Cancer was to adopt a uniﬁed approach
for evaluating the causes of cancer and the effectiveness of
interventions in order to ensure that the recommendations were as
robust and authoritative as possible.
Further work based on a systematic and possibly continuous
process of updating will be needed in the future; recent systematic
reviews of the scientiﬁc evidence from this project or elsewhere
could provide a basis for the timely updating of the recommen-
dations or other parts of the Code.
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